Oliver Sartor, MD

Oliver Sartor, MD, is a medical oncologist with a special focus on prostate cancer over the past 34 years. He is currently professor of medical oncology; chief, Genitourinary Cancers Disease Group; and director, Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN.

Dr Sartor has published more than 500 peer-reviewed publications, the vast majority of which focus on clinical and translational studies in prostate cancer, and has led multiple national and international advanced prostate cancer trials, including those pivotal to the FDA approvals of samarium-153, cabazitaxel, radium-223, and ¹⁷⁷Lu-PSMA-617. These trials have been practice changing and have helped to shape the current therapeutic landscape in advanced and castration-resistant prostate cancer. He has served as co–principal investigator on trials such as RTOG 0621 and NRG-009. His studies on prostate cancer are devoted to improving the care of patients with prostate cancer and understanding the scientific underpinnings of prostate cancer biology. In addition, Dr Sartor serves as vice-chair of the NRG Oncology Genitourinary Cancer Committee.